




Available at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.elsevier.com/locate/hemonc](http://www.elsevier.com/locate/hemonc)



REVIEW ARTICLE

# Physical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation: Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBT) Group



Jaleel Mohammed<sup>a,b,\*</sup>, Mahmoud Aljurf<sup>a,b</sup>, Abdulaziz Althumayri<sup>a</sup>, Muntaha Almansour<sup>a</sup>, Ahmed Alghamdi<sup>a</sup>, Amir Ali Hamidieh<sup>c</sup>, Alaa ElHaddad<sup>d</sup>, Tarek Ben Othman<sup>e</sup>, Ali Bazarbachi<sup>f</sup>, Fahad Almohareb<sup>a</sup>, Mohsen Alzahrani<sup>h</sup>, Salam S. Alkindi<sup>i</sup>, Fahad Alsharif<sup>a</sup>, Waleed Da'na<sup>j</sup>, Hani Alhashmi<sup>k</sup>, Mohamed A. Bekadja<sup>l</sup>, Salem H. Al-Shammari<sup>m</sup>, Asma El Quessar<sup>n</sup>, Tariq M. Satti<sup>o</sup>, Naif Aljohani<sup>p</sup>, Walid Rasheed<sup>a</sup>, Ardeshir Ghavamzadeh<sup>c</sup>, Naeem Chaudhri<sup>a</sup>, Shahrukh K. Hashmi<sup>b,g</sup>

<sup>a</sup> Department of Physical Therapy and Rehabilitation, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

<sup>b</sup> Rehabilitation department, Physical Therapy Association for Graft Versus Host Disease, Swindon, UK

<sup>c</sup> Stem Cell Transplantation, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran

<sup>d</sup> Oncology, National Cancer Institute, Cairo University, Giza, Egypt

<sup>e</sup> Hematology, Centre National De Greffe De La Moelle Osseuse, Tunis, Tunisia

<sup>f</sup> Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon

<sup>g</sup> Hematology/Oncology, Mayo Clinic, Rochester, MN, USA

<sup>h</sup> Hepatology & Hematology, National Guard Health Affairs, Riyadh, Saudi Arabia

<sup>i</sup> Hematology, Sultan Qaboos University Hospital, Al-Khoud, Oman

<sup>j</sup> Implantology/Hematology, King Hussein Cancer Center, Amman, Jordan

<sup>k</sup> Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, Dammam, Saudi Arabia

<sup>l</sup> Department of Hematology and Cell Therapy, University Hospital EHU 1er November, Oran, Algeria

<sup>m</sup> Stem Cell Transplant, Kuwait Cancer Control Center, Kuwait

<sup>n</sup> Hematology and Oncology Pediatric Department, University Hospital Ibn Rochd, Casablanca, Morocco

\* Corresponding author at: Physical Therapy Association for Graft Versus Host Disease, 12 Boscombe Down, Gloucester, GL2 2FT, Swindon, UK.

E-mail address: [qualityfrlife@gmail.com](mailto:qualityfrlife@gmail.com) (J. Mohammed).

<sup>o</sup> Bone Marrow Transplant, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan

<sup>p</sup> Adult Bone Marrow Transplant, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia

Received 29 November 2018; accepted 14 December 2018

Available online 11 January 2019

#### KEYWORDS

Hematopoietic stem cell transplantation;  
Physical therapy;  
Rehabilitation

#### Abstract

**Background:** Patients undergoing hematopoietic stem cell transplantation (HSCT) are often referred for physical therapy (PT) to help improve their quality of life. However, to our knowledge there is no clear PT pathway to guide therapists and patients before, during, and after HSCT.

**Methods:** A comprehensive literature review was carried out exploring the role and benefits of PT in HSCT patients. The current evidence was complimented with recommendations and opinions from the experts in the field, which included PT's and hematology consultants from PTAGVHD and the EMBMT group.

**Result:** A clear pathway and protocol as a working guide for rehabilitation professionals working with the HSCT patient's was developed.

**Conclusion:** This paper not only reviews the current evidence on safe PT practice but also puts forward a protocol and pathway for HSCT rehabilitation, highlights the importance of individualized exercise intervention for HSCT patients, and outlines safe practice guidelines for the physical therapists working in this field.

© 2019 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

#### Contents

|   |     |
|---|-----|
| Introduction . . . . .                              | 128 |
| Objectives . . . . .                                | 129 |
| The need for PT clinical pathway for HSCT . . . . . | 129 |
| PT pathway . . . . .                                | 129 |
| HSCT pretransplant PT assessment . . . . .          | 129 |
| Subjective evaluation . . . . .                     | 129 |
| Objective assessment . . . . .                      | 129 |
| Pretransplant physical fitness . . . . .            | 129 |
| Inpatient PT protocol . . . . .                     | 130 |
| Platelet count . . . . .                            | 130 |
| Caution . . . . .                                   | 130 |
| Blood transfusion patients . . . . .                | 131 |
| Patients with complications . . . . .               | 131 |
| Prioritizing patients . . . . .                     | 131 |
| Exercise prescription and progression . . . . .     | 131 |
| Discharge and plan . . . . .                        | 131 |
| Outpatient long-term PT follow-up . . . . .         | 131 |
| Take away points . . . . .                          | 131 |
| Conflicts of interest . . . . .                     | 131 |
| Authors' contributions . . . . .                    | 132 |
| References . . . . .                                | 132 |

#### Introduction

Physical therapy (PT) has been advocated [1] as a promising adjunct to treatment during and after hematopoietic stem cell transplantation (HSCT) because of its multidimensional effectiveness [2]. There is growing evidence that a signifi-

cant difference in strength, endurance, lung function, and quality of life can be achieved with PT intervention [3]. However, to achieve the desired results in the setting of HSCT, type, frequency, duration, and intensity of the exercise should be well planned and executed to reflect the diverse needs of individual patients [4].

This article has been developed by the Rehabilitation Association for Hematopoietic Stem Cell Transplantation (RHSC), formerly known as PTAGVHD (Physical Therapy Association Graft Versus Host Disease), team with the support and input from the Quality of Life Committee of the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT). The main aim of this work is to recommend a framework for the hospitals involved in HSCT to help maximize the benefit from PT services. The article is combined with evidence-based recommendations along with opinions from experts from within the field to help structure service provision.

## Objectives

1. Define a clear PT pathway for patients before, during, and after HSCT.
2. Recommend subjective and objective measures to help monitor and relay progress to the patients and the multidisciplinary medical team involved in their care.
3. Highlight the importance of individualized exercise intervention for hsct patients. the importance of individualized exercise intervention for HSCT patients.
4. Recommend safe practice PT guidelines for HSCT inpatients.

## The need for PT clinical pathway for HSCT

Clinical pathways are often created to help improve patient services, enhance recovery, standardize practice for research and data collection, ensure continuity and quality of care, better utilize resources, to be cost-effective, and streamline cases based on the priority, thereby positively influencing the opinions of the stakeholders involved in the provision of the services [5–9]. Considering the extent of complications both before and after transplant, which the potential HSCT patients present with, it is vital that these patients receive a structured and standardized care that can help in not only early detection of musculoskeletal (MSK)-related complications but also timely intervention to prevent functional loss.

## PT pathway

### HSCT pretransplant PT assessment

One of the main rationale behind obtaining the pretransplant functional capacity score is to help monitor any deterioration after transplantation, such as development of the MSK manifestations such as chronic graft versus host disease (cGVHD) or other complications. Thus, each hospital should develop their own comprehensive PT assessment which will enable them to capture the diverse functional elements.

### Subjective evaluation

It is recommended that the subjective evaluation includes, apart from the usual PT assessment, the following:

1. Existing MSK-related conditions: This helps in planning both pretransplant and post-transplant rehabilitation with a focus on existing functional incapacity and to also differentiate between post-transplant complications and existing conditions.
2. Occupation: Discussing return to work (if applicable) at the initial assessment can help physical therapists understand the area that needs more focus during rehabilitation and perhaps plan an early return to work depending on patients' individual medical and physical condition. If possible, some of the work-related functional evaluation tests can be carried out at this stage and can be vital in not only monitoring but also for making work-related recommendations to the patients and their employers.
3. Medications: The physical therapists should make themselves aware of the history of medications, which should be obtained from either the patients or their respective doctors and PTs, including the potential side effects in relation to patient's potential recovery [10].

## Objective assessment

Wherever possible, each pre-HSCT patient should be offered the following PT assessment and the outcomes recorded in the patient notes according to the individual hospital recording system. The aim is to obtain an overall body functional capacity; however, patients who are not able to undergo this comprehensive test should aim to get a minimum of one upper limb and one lower limb objective measure along with completion of a quality of life questionnaire and a functional questionnaire:


1. Upper and lower limb active range of motion [11] (goniometer or other objective measure).
2. Jamar Grip and Pinch Strength [12].
3. Upper and Lower Limb Strength Test (use a valid and reliable method).
4. 30-second Chair-Stand Test [13].
5. 6-minute Walk Test [14].
6. EORTC QLQ-C30 [15] Questionnaire.
7. Lower Extremity Functional Scale (LEFS) [16].
8. Disabilities of the Arm, Shoulder and Hand Questionnaire (QuickDASH) [17].

The physical therapist should communicate any existing functional incapacity or concerns to the multidisciplinary team involved in patient care and make appropriate interventional plan for the patient.

Patients requiring PT input prior to transplant should be scheduled for appropriate intervention and communicate the rehabilitation to the inpatient physical therapist highlighting the risk areas (Fig. 1).

## Pretransplant physical fitness

The pretransplant physical assessment can also be beneficial in determining the existing fitness level of a patient, as several studies have indicated a positive post-transplant outcome for patients with good pretransplant fitness levels



**Fig. 1** Physical therapy (PT) pathway for hematopoietic stem cell transplantation (HSCT) patients.

[18]. Improvements in muscle strength and cardiopulmonary fitness before HSCT have been found to be crucial for maintaining post-treatment physical function, especially in elderly individuals with acute GVHD requiring a long-term stay in a protective environment [19].

### Inpatient PT protocol

For all patients with documented baseline parameters (pre-transplant), an individualized strength, endurance, cardiovascular, and balance training should be prescribed by the physical therapist based on the patient's individual ability. It should be noted that the exercise program needs tailoring based on patient's day-to-day symptoms throughout the inpatient admission period.

### Platelet count

Although low platelet (<20,000/mcL) count has historically been a concern and considered a contraindication for exercises, recent studies have shown that most HSCT patients are able to tolerate and benefit from exercises despite low platelet counts (<10,000/mcL) [20,21]. Furthermore, no association between minor bleeding events and intensities of PT interventions or between minor bleeding events and platelet counts in children under the age of 18 [22] was reported. Although these studies lack in their quality, their findings can be suggestive for physical therapists that the entire clinical situation of the individual patient should be taken into account when weighing the risk and benefits of exercise interventions rather than just solely relying on the platelet count itself. This is encouraging for both patients

**Table 2** Exercises Versus Platelet Count.

| Platelet count    | Exercise intensity    |
|-------------------|-----------------------|
| 5000/mcL          | Very light            |
| 5000–20,000/mcL   | Light to moderate     |
| 21,000–30,000/mcL | Moderate              |
| 31,000–50,000/mcL | Moderate to intensive |

and rehabilitation specialists working with this population considering the high risk and associated complications due to reduced mobility. For the ease of therapists, a safe practice guideline for exercise intensities are summarized in Table 1.

It is vital that the physical therapists involved in patient care should modify the exercise intensity to reflect individual patient's medical and physical condition on a day-to-day basis. Platelet counts are outlined in Table 2 to help guide exercise programs; however, as discussed earlier, the clinician should use his/her own clinical judgment before progressing the patient to ensure patient safety.

### Caution

In some patients, platelet or blood transfusions would be recommended before training if the platelet count and hemoglobin levels are below 10,000/ $\mu$ L and 8 g/100 mL, respectively [23]. Patients who have a hemoglobin level below 80 g /100mL should not receive any PT management, however, the risks and benefits of exercising with low hemoglobin should also be considered on an individual basis within the patient's overall clinical picture.

**Table 1** Exercise intensities.

| Very light  | Light   | Moderate                                       | Intensive                          |
|---|---|--|------------------------------------|
| AROM/AAROM  | Transfers   | Muscle motor training                          | Stretching/elongation              |
| Essential ADL (sitting at the edge of the bed or in the bed/ chair) | Limited ambulation (in the room)                          | Dynamic balance/coordination (uneven surfaces) | Strengthening                      |
| Grooming  | AROM  | Endurance                                      | Progressive resistive exercises    |
| Bed mobility (rolling, supine to sit on the edge of the bed)        | ADL (standing at the edge of the bed)                     | Unlimited ambulation (out of the room)         | Jumping, obstacle course, climbing |
| Therapeutic activity in the bed                                     | Static balance on even and stable surfaces (mat or floor) |  |                                    |

*Note.* ADL = activities of daily living; AROM = active range of motion; AAROM = active assisted range of motion.

## Blood transfusion patients

Until recently, the PT intervention during blood transfusion was believed to be contraindicated, but recent studies have provided preliminary evidence that participation in a well-monitored PT session may be safe for individuals with hematologic malignancies and for those who are receiving a red blood cell (RBC) transfusion. Furthermore, adverse events related to RBC transfusion are believed not to be influenced by PT intervention [24].

## Patients with complications

Post HSCT patients might develop certain complications resulting in their admission to the intensive care unit (ICU). These patients, on return from the ICU, can benefit from being reassessed for their functional capacity so that their physical therapy plan reflects their current medical and physical status.

## Prioritizing patients

A physical therapist should prioritize the delivery of the PT sessions on a case-by-case scenario, for example, more PT resources should be dedicated to patients who are identified as high risk compared with those who are independent and are able to follow exercise prescription (these patients might be given an exercise log). This also means that some patients might even require two to three sessions a day (e.g., patients with GVHD).

## Exercise prescription and progression

- The exercise prescribed to patients should be aimed at progressing various parameters (i.e., strength, endurance, cardiovascular, balance, and function).
- The baseline parameters should be retested each week or as deemed appropriate depending on the patient's condition and progression. However, all patients should receive an initial assessment and predischarge assessment.
- The physical therapist should record each exercise session, the progression plan, and communicate this to the rehabilitation team alongside the nurse and the consultant/doctor.

## Discharge and plan

- Patients due for discharge should receive a full PT assessment according to the pretransplant protocol and this should be compared with the pretransplant scores to help identify the need for outpatient rehabilitation.
- Appropriate arrangements for outpatient PT should be made before the patient is discharged from the hospital.
- Home exercise and precaution education should be provided to the patients before they are sent home.

## Outpatient long-term PT follow-up

A significant proportion of the transplant patients show some signs of cGVHD [25,26]. PTs can be best utilized in

the early detection of MSK-related cGVHD, especially for those patients in whom the impact is on muscle power, fascia, functional capacity, and quality of life and in those with advanced sclerotic skin changes. With the baseline functional score already available to the physical therapists from the pretransplant assessment record, it should be relatively easy to correlate any deterioration in patient's functional capacity, thus helping in early detection, flagging, and intervention. However, to achieve this, it is important that patients are offered full-body functional evaluation after transplantation at 4 weeks, 8 weeks, 12 weeks, 15 weeks, 18 weeks, and 21 weeks. This repeated assessment could help in monitoring subtle changes in the myofascial level and the patient-reported symptoms. Physical therapists should make themselves familiar with the myofascial movement pattern so that the measurements of the movement reflect the myofascial chain and not just the joint range of motion.

Physical therapists who are trained in using diagnostic ultrasound can also utilize this technology to help monitor the changes in the skin/fascia on selective sites such as hand, forearm, calf, hamstrings, and spinal area during each assessment to monitor changes.

The rehabilitation should follow SMART (specific, measurable, attainable, realistic, and time bound) goals, which should be reflected via individualized exercise prescription plan. Some patients might also need functional restoration program to help them return to work or sports activities, which again will need a careful planning and execution on behalf of the physical therapist along with the multidisciplinary team. The return-to-work recommendations must only be made by physical therapists or health-care professionals who are experienced in the occupational health field and qualified to do so.

## Take away points

1. HSCT patients can benefit from a structured PT pathway to ensure safety, continued service, enhanced recovery, and reduced burden of disease before, during, and after transplant rehabilitation.
2. A well-defined personalized exercise prescription program is vital in achieving individual patient goals.
3. Whole-body functional assessment should be considered for all patients undergoing HSCT to help monitor and detect any MSK changes.
4. Knowledge of myofascial movement pattern and chains is essential in capturing the true functional incapacity in patients.
5. Ongoing assessments at regular intervals can help in early detection of MSK-related complication, thereby helping patients with timely intervention.
6. Communicating between various health-care professionals involved in the patient care can be a key to a successful patient journey in the hospital.

## Conflicts of interest

There are no conflicts of interest to disclose from any authors.

## Authors' contributions

J.M., M.A., and S.H. wrote the first draft of the manuscript. All authors contributed substantially to the conception, acquisition, analysis, and interpretation of the data for the work. No funding was received from any source.

## References

- [1] Hashmi S, Carpenter P, Khera N, Tichelli A, Savani BN. Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. *Biol Blood Marrow Transplant* 2015;21:225–32.
- [2] Wiskemann J, Huber G. Physical exercise as adjuvant therapy for patients undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2008;41:321–9.
- [3] Baumann FT, Kraut L, Schüle K, Bloch W, Fauser AA. A controlled randomized study examining the effects of exercise therapy on patients undergoing haematopoietic stem cell transplantation. *Bone Marrow Transplant* 2010;45:355–62.
- [4] Steinberg A, Asher A, Bailey C, Fu JB. The role of physical rehabilitation in stem cell transplantation patients. *Support Care Cancer* 2015;23:2447–60.
- [5] Kinsman L, Rotter T, James E, Snow P, Willis J. What is a clinical pathway? Development of a definition to inform the debate. *BMC Med* 2010;8:31.
- [6] Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. *Lancet Oncol* 2014;15:e112–8.
- [7] Butow P, Price MA, Shaw JM, Turner J, Clayton JM, Grimison P, et al. Clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients: Australian guidelines. *Psychooncology* 2015;24:987–1001.
- [8] Lawal AK, Rotter T, Kinsman L, Machotta A, Ronellenfitsch U, Scott SD, et al. What is a clinical pathway? Refinement of an operational definition to identify clinical pathway studies for a Cochrane systematic review. *BMC Med* 2016;14:35.
- [9] Ishikawa A, Otaka Y, Kamisako M, Suzuki T, Miyata C, Tsuji T, Matsumoto H, Kato J, Mori T, Okamoto S, Liu M. Factors affecting lower limb muscle strength and cardiopulmonary fitness after allogeneic hematopoietic stem cell transplantation. *Supportive Care in Cancer*. 2018 Jan;1:1–8.
- [10] Mohammed J, Akomolafe T, Aljurf M, Savani B, Hashmi SK. 'To treat or not to treat': raising awareness on the effects of graft versus host disease drugs on musculoskeletal system. *Bone Marrow Transplant* 2018;53:909–12.
- [11] Mohammed J, AlGhamdi A, Hashmi SK. Full-body physical therapy evaluation for pre-and post-hematopoietic cell transplant patients and the need for a modified rehabilitation musculoskeletal specific grading system for chronic graft-versus-host disease. *Bone Marrow Transplant* 2018;53:625–7.
- [12] Bailey C, Asher A, Kim S, Shinde A, Lill M. Evaluating hand grip strength prior to hematopoietic stem cell transplantation as a predictor of patient outcomes. *Rehabil Oncol* 2018;36:172–9.
- [13] Hacker ED, Larson J, Kujath A, Peace D, Rondelli D, Gaston L. Strength training following hematopoietic stem cell transplantation. *Cancer Nurs* 2011;34:238–49.
- [14] Wiskemann J, Dreger P, Schwerdtfeger R, Bondong A, Huber G, Kleindienst N, et al. Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation. *Blood* 2011;117:2604–13.
- [15] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365–76.
- [16] Binkley JM, Stratford PW, Lott SA, Riddle DL. North American Orthopaedic Rehabilitation Research Network. The Lower Extremity Functional Scale (LEFS): scale development, measurement properties, and clinical application. *Phys Ther* 1999;79:371–83.
- [17] Gummesson C, Ward MM, Atroshi I. The shortened Disabilities of the Arm, Shoulder and Hand Questionnaire (Quick DASH): validity and reliability based on responses within the full-length DASH. *BMC Musculoskelet Disord* 2006;7:44.
- [18] Van Haren IE, Staal JB, Poppinga CM, Atsma F, Hoogeboom TJ, Blijlevens NM, et al. Physical exercise prior to hematopoietic stem cell transplantation: a feasibility study. *Physiother Theory Pract* 2018;34:747–56.
- [19] Ishikawa A, Otaka Y, Kamisako M, Suzuki T, Miyata C, Tsuji T, et al. Factors affecting lower limb muscle strength and cardiopulmonary fitness after allogeneic hematopoietic stem cell transplantation. *Support Care Cancer* 2018, in press.
- [20] Rexer P, Kanphade G, Murphy S. Feasibility of an exercise program for patients with thrombocytopenia undergoing hematopoietic stem cell transplant. *J Acute Care Phys Ther* 2016;7:55–64.
- [21] Rosenfeldt AB, Covert S. Physical therapy intervention for an individual with severe thrombocytopenia. *J Acute Care Phys Ther* 2017;8:133–40.
- [22] Ibanez K, Espiritu N, Souverain RL, Stimler L, Ward L, Riedel ER, et al. Safety and feasibility of rehabilitation interventions in children undergoing hematopoietic stem cell transplant with thrombocytopenia. *Arch Phys Med Rehabil* 2018;99:226–33.
- [23] Wolin KY, Ruiz JR, Tuchman H, Lucia A. Exercise in adult and pediatric hematological cancer survivors: an intervention review. *Leukemia* 2010;24:1113–20.
- [24] Rosenfeldt AB, Pilkey LM, Butler RS. Physical therapy intervention during a red blood cell transfusion in an oncologic population: a preliminary study. *J Acute Care Phys Ther* 2017;8:20–7.
- [25] Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. *Blood Rev* 2006;20:15–27.
- [26] Margolis J, Vogelsang G. Chronic graft-versus-host disease. *J Hematother Stem Cell Res* 2000;9:339–46.